Memory Pharmaceuticals has achieved a $2.0 million milestone related to its PDE10 collaboration with Amgen, a strategic alliance entered into in October 2005 focused on the development of PDE10 inhibitors as potential treatments for certain neurological and psychiatric disorders. The achievement of the milestone was triggered by preclinical work on PDE10 inhibitors, which satisfied a set of criteria pre-defined by Amgen. Separately, Memory Pharmaceuticals announced that Amgen plans to increas...